您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > MMI-0100
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
MMI-0100
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
CAS NO:1039342-24-9
包装与价格:
包装价格(元)
5mg电议
10mg电议
25mg电议
50mg电议
100mg电议

产品介绍
MMI-0100 是一种细胞渗透性肽抑制剂,抑制丝裂原活化蛋白激酶活化蛋白激酶 II (MK2)。MMI-0100 在体内外减少内膜增生。MMI-0100 抑制 IL-6 表达而不影响 IL-8 表达。MMI-0100 抑制纤维化过程,例如静脉移植疾病。
生物活性

MMI-0100 is a cell-permeant peptide inhibitor of mitogen activated protein kinase activated protein kinase II (MK2). MMI-0100 reduces intimal hyperplasia ex vivo and in vivo. MMI-0100 suppressesIL-6expression without effect onIL-8expression. MMI-0100 suppresses fibrotic processes such as vein graft disease[1].

体外研究
(In Vitro)

Naphthofluorescein (compound 19) (0-10 μM; 24 hours) suppresses the HIF-1 reporter activity in a concentration-dependent manner.[1].
MMI-0100 (0.25 and 0.5 mM; 24 hours) slightly increases cell proliferation in both cell types compared to control cells treated with 20 ng/ml TNF-α alone[1].
MMI-0100 (1 mM) treatment also increases both EC (11%) and SMC (7%) proliferation as compared to control, this response is not as robust as that induced by treatment with 0.5 mM MMI-0100[1].
MMI-0100 does not induce EC apoptosis at any dose[1].

Cell Viability Assay[1]

Cell Line:human endothelial cell (EC) and smooth muscle cell (SMC)
Concentration:0.25, 0.5, and 1 mM
Incubation Time:24 hours
Result:Slightly increased cell proliferation in both cell types compared to control cells.
体内研究
(In Vivo)

MMI-0100 (100 μM; 28 days) inhibits intimal hyperplasia in a mouse vein graft model[1].

Animal Model:12-week-old C57Bl/6 wild type mice (intimal hyperplasia)[1]
Dosage:100 μM
Administration:vein graft, 28 days
Result:Diminished wall thickness at all postoperative time points in vein grafts treated with MMI-0100, with a ratio of 2.6-fold thicker at 4 weeks, compared to 4.7-fold thicker at 4 weeks in control grafts.
Clinical Trial
分子量

2283.64

性状

Solid

Formula

C98H171N37O26

CAS 号

1039342-24-9

Sequence Shortening

YARAAARQARAKALARQLGVAA

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Sealed storage, away from moisture and light, under nitrogen

Powder-80°C2 years
-20°C1 year

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen)

溶解性数据
In Vitro: 

H2O : 100 mg/mL(43.79 mM;Need ultrasonic)

配制储备液
浓度溶剂体积质量1 mg5 mg10 mg
1 mM0.4379 mL2.1895 mL4.3790 mL
5 mM0.0876 mL0.4379 mL0.8758 mL
10 mM0.0438 mL0.2189 mL0.4379 mL
*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80℃, 6 months; -20℃, 1 month (sealed storage, away from moisture and light, under nitrogen)。-80℃ 储存时,请在 6 个月内使用,-20℃ 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂: PBS

    Solubility: 14.29 mg/mL (6.26 mM); Clear solution; Need ultrasonic

*以上所有助溶剂都可在本网站选购。